Dual-mTOR inhibitor Rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity

Bone metastasis is the leading cause of prostate cancer (PCa) mortality, frequently marking the progression to castration-resistant PCa. In this study, we compared the molecular pathways enriched in a set of bone metastasis from breast and prostate cancer from snap-frozen tissue. To further model PCa drug resistance mechanisms, we used two patient-derived xenografts (PDX) models of bone-metastatic PCa, BM18 and LAPC9.EGA study EGAS00001004431

骨转移是前列腺癌（prostate cancer, PCa）致死的首要原因，通常标志着疾病进展至去势抵抗性前列腺癌（castration-resistant PCa）。本研究针对一批取自乳腺癌与前列腺癌骨转移灶的速冻组织，对比分析了其中富集的分子通路。为进一步模拟前列腺癌的耐药机制，本研究采用了两种骨转移性前列腺癌的患者来源异种移植模型（patient-derived xenografts, PDX）：BM18与LAPC9。本研究对应EGA研究EGAS00001004431。